Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

$7.70 -0.30 (-3.75 %)
(As of 12/12/2017 12:55 PM ET)
Previous Close$8.00
Today's Range$7.62 - $8.20
52-Week Range$7.00 - $17.20
Volume731,700 shs
Average Volume594,721 shs
Market Capitalization$431.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Debt-to-Equity Ratio0.14%
Current Ratio7.60%
Quick Ratio7.60%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$106.41 million
Price / Sales3.90
Cash Flow$0.41 per share
Price / Cash18.90
Book Value$2.32 per share
Price / Book3.32

Profitability

Trailing EPS($1.66)
Net Income$16.45 million
Net Margins-172.27%
Return on Equity-62.64%
Return on Assets-29.08%

Miscellaneous

Employees127
Outstanding Shares53,880,000

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.64) by $0.04. The biopharmaceutical company earned $6.18 million during the quarter, compared to analysts' expectations of $5.35 million. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.

When will Cytokinetics make its next earnings announcement?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Cytokinetics.

Where is Cytokinetics' stock going? Where will Cytokinetics' stock price be in 2017?

10 Wall Street analysts have issued 12 month price targets for Cytokinetics' stock. Their forecasts range from $10.00 to $25.00. On average, they anticipate Cytokinetics' share price to reach $17.90 in the next year. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

  • 1. Cantor Fitzgerald analysts commented, "CYTK is on track for the readout of tirasemtiv in the pivotal VITALITY-ALS study at the International Symposium on ALS/MND (December 8-10)." (9/26/2017)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
  • 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
  • 4. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)
  • 5. HC Wainwright analysts commented, "We have adjusted our 2017 estimates downward accordingly. The company had a net loss of $4.3M in 4Q16, or ($0.81) per share based on shares adjusted for the 1-for-10 reverse split effective on February 27. 2016. The loss was lower than our estimate of $4.9M due to improved expense management. For the fiscal year 2016, TearLab had $28M in revenue, representing 11% growth over that of 2015, and $19.9M in net loss. In our view, the softened growth rate in the Flex program and in international markets could continue in 2017. Therefore, we currently project a conservative low single-digit growth in revenue in 2017. Our valuation of the company has decreased from $140M to $105M. Excluding debt, our estimated market value of the firm is $79M. Assuming 6.5M shares outstanding at the end of 2017, we project a 12-month price target of $12 per share. Our previous price target was $2 before the reverse split. Importantly, TearLab has begun a process to explore strategic alternatives, which does not preclude a sale of the company." (3/13/2017)

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Independent Chairman of the Board (Age 74)
  • Robert I. Blum, President, Chief Executive Officer, Director (Age 53)
  • Ching Jaw, Chief Financial Officer, Senior Vice President (Age 54)
  • Sharon A. Barbari, Executive Vice President - Finance (Age 62)
  • Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development (Age 52)
  • Peter S. Roddy, Senior Vice President, Chief Accounting Officer (Age 57)
  • David W. Cragg, Senior Vice President - Human Resources (Age 61)
  • Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance (Age 65)
  • Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development (Age 56)
  • Elisabeth Schnieders Ph.D., Senior Vice President - Business Development (Age 50)

Who owns Cytokinetics stock?

Cytokinetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (10.10%), Janus Henderson Group PLC (5.16%), Pinnacle Associates Ltd. (1.87%), Wasatch Advisors Inc. (1.30%), Bank of New York Mellon Corp (1.03%) and Principal Financial Group Inc. (0.85%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Who sold Cytokinetics stock? Who is selling Cytokinetics stock?

Cytokinetics' stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., Wasatch Advisors Inc., Public Employees Retirement System of Ohio, Teachers Retirement System of The State of Kentucky, Keybank National Association OH, California State Teachers Retirement System and SG Americas Securities LLC. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.

Who bought Cytokinetics stock? Who is buying Cytokinetics stock?

Cytokinetics' stock was purchased by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Ameriprise Financial Inc., Janus Henderson Group PLC, Los Angeles Capital Management & Equity Research Inc., Granite Investment Partners LLC, Essex Investment Management Co. LLC, Principal Financial Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Cytokinetics.

How do I buy Cytokinetics stock?

Shares of Cytokinetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of Cytokinetics stock can currently be purchased for approximately $7.70.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $431.08 million and generates $106.41 million in revenue each year. The biopharmaceutical company earns $16.45 million in net income (profit) each year or ($1.66) on an earnings per share basis. Cytokinetics employs 127 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  355 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytokinetics (NASDAQ:CYTK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.913.003.103.10
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $18.27$21.82$21.50$20.40
Price Target Upside: 152.04% upside53.11% upside59.26% upside43.16% upside

Cytokinetics (NASDAQ:CYTK) Consensus Price Target History

Price Target History for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017Needham & Company LLCDowngradeStrong-Buy -> Buy$22.00 -> $12.00LowView Rating Details
11/22/2017Morgan StanleyReiterated RatingOverweight -> Overweight$25.00 -> $17.00N/AView Rating Details
11/22/2017Cantor FitzgeraldDowngradeOverweight -> Neutral$21.00 -> $10.00N/AView Rating Details
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $13.00N/AView Rating Details
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/AView Rating Details
11/21/2017HC WainwrightLower Price TargetBuy -> Buy$26.00 -> $17.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$24.00N/AView Rating Details
8/4/2017CowenReiterated RatingBuy$19.00LowView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$16.00 -> $14.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($0.71)N/AView Earnings Details
10/26/2017Q3 2017($0.64)($0.60)$5.35 million$6.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.57)($0.60)$5.28 million$3.05 millionViewListenView Earnings Details
2/16/2017Q416($0.39)$0.16$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.27)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.28)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cytokinetics (NASDAQ:CYTK) Earnings Estimates

2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.66)($0.66)($0.66)
Q3 20171($0.70)($0.70)($0.70)
Q4 20171($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 73.72%
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/2/2017Caryn Gordon McdowellInsiderSell4,260$12.94$55,124.40View SEC Filing  
11/1/2017Fady Ibraham MalikEVPSell7,321$13.39$98,028.19View SEC Filing  
11/1/2017Robert I BlumCEOSell5,000$13.51$67,550.00View SEC Filing  
10/6/2017Caryn Gordon McdowellInsiderSell13,181$15.49$204,173.69View SEC Filing  
10/2/2017Robert I BlumCEOSell5,000$14.59$72,950.00View SEC Filing  
9/6/2017Caryn Gordon McdowellInsiderSell10,131$14.60$147,912.60View SEC Filing  
9/1/2017Robert I BlumCEOSell5,000$14.71$73,550.00View SEC Filing  
8/31/2017Bradley Paul MorganSVPSell118,330$15.00$1,774,950.00View SEC Filing  
8/31/2017Santo J CostaDirectorSell5,000$15.00$75,000.00View SEC Filing  
8/29/2017Santo J CostaDirectorSell5,000$14.00$70,000.00View SEC Filing  
8/8/2017Caryn Gordon McdowellInsiderSell11,348$12.47$141,509.56View SEC Filing  
8/1/2017Robert I BlumCEOSell5,000$13.79$68,950.00View SEC Filing  
7/3/2017Robert I BlumCEOSell5,000$12.14$60,700.00View SEC Filing  
6/1/2017Robert I BlumCEOSell5,000$13.62$68,100.00View SEC Filing  
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.88View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytokinetics (NASDAQ CYTK) News Headlines

Source:
DateHeadline
5 Stocks To Watch For December 11, 2017 - Benzinga5 Stocks To Watch For December 11, 2017 - Benzinga
www.benzinga.com - December 11 at 5:22 PM
Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 MillionCytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - December 10 at 6:36 AM
Cytokinetics (CYTK) & The Competition Financial SurveyCytokinetics (CYTK) & The Competition Financial Survey
www.americanbankingnews.com - December 8 at 5:14 PM
Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MNDCytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
finance.yahoo.com - December 8 at 5:04 PM
Cytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from BrokeragesCytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 3:52 PM
-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter
www.americanbankingnews.com - December 8 at 3:30 PM
Contrasting Cytokinetics (CYTK) & The CompetitionContrasting Cytokinetics (CYTK) & The Competition
www.americanbankingnews.com - December 7 at 9:24 AM
Cytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.comCytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.com
www.streetinsider.com - December 1 at 5:01 PM
Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MNDCytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND
finance.yahoo.com - December 1 at 5:01 PM
New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve ActivationNew Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation
finance.yahoo.com - November 30 at 5:07 PM
Cytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.comCytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.com
www.streetinsider.com - November 30 at 10:09 AM
Needham & Company LLC Downgrades Cytokinetics (CYTK) to BuyNeedham & Company LLC Downgrades Cytokinetics (CYTK) to Buy
www.americanbankingnews.com - November 29 at 8:44 AM
ETFs with exposure to Cytokinetics, Inc. : November 27, 2017ETFs with exposure to Cytokinetics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:06 PM
Cytokinetics, Incorporated (CYTK) Downgraded by Cantor Fitzgerald to "Neutral"Cytokinetics, Incorporated (CYTK) Downgraded by Cantor Fitzgerald to "Neutral"
www.americanbankingnews.com - November 22 at 12:56 PM
Reviewing Cytokinetics, (CYTK) and AveXis (AVXS)Reviewing Cytokinetics, (CYTK) and AveXis (AVXS)
www.americanbankingnews.com - November 22 at 11:30 AM
Cytokinetics, Incorporated (CYTK) Receives "Overweight" Rating from Morgan StanleyCytokinetics, Incorporated (CYTK) Receives "Overweight" Rating from Morgan Stanley
www.americanbankingnews.com - November 22 at 8:52 AM
Cytokinetics, Incorporated (CYTK) Expected to Announce Quarterly Sales of $4.83 MillionCytokinetics, Incorporated (CYTK) Expected to Announce Quarterly Sales of $4.83 Million
www.americanbankingnews.com - November 22 at 4:02 AM
Cytokinetics, Incorporated (CYTK) Stock Rating Lowered by ValuEngineCytokinetics, Incorporated (CYTK) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - November 22 at 12:20 AM
OSUR Turns Heads, MRSN To Report Data By Year-end, CYTK Loses VitalityOSUR Turns Heads, MRSN To Report Data By Year-end, CYTK Loses Vitality
www.nasdaq.com - November 21 at 11:00 PM
Swinging at Lou Gehrigs disease, Peninsula drug maker strikes outSwinging at Lou Gehrig's disease, Peninsula drug maker strikes out
www.bizjournals.com - November 21 at 6:00 PM
Interesting CYTK Put And Call Options For January 2018Interesting CYTK Put And Call Options For January 2018
www.thestreet.com - November 21 at 5:59 PM
Cytokinetics neuro-degenerative drug fails late-stage trialCytokinetics' neuro-degenerative drug fails late-stage trial
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics shares drop 31% on late-stage ALS drug failureCytokinetics shares drop 31% on late-stage ALS drug failure
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALSCytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALS
finance.yahoo.com - November 21 at 5:59 PM
Why Is Cytokinetics Plunging Today?Why Is Cytokinetics Plunging Today?
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes?Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes?
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics Crumbles on Late-Stage ResultsCytokinetics Crumbles on Late-Stage Results
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics CEO: Optimism still there despite ALS drug s...Cytokinetics CEO: Optimism still there despite ALS drug s...
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics, Incorporated (CYTK) Earns Outperform Rating from JMP SecuritiesCytokinetics, Incorporated (CYTK) Earns Outperform Rating from JMP Securities
www.americanbankingnews.com - November 21 at 3:24 PM
Needham & Company LLC Downgrades Cytokinetics, Incorporated (CYTK) to BuyNeedham & Company LLC Downgrades Cytokinetics, Incorporated (CYTK) to Buy
www.americanbankingnews.com - November 21 at 3:24 PM
Cytokinetics,s (CYTK) "Overweight" Rating Reiterated at Piper Jaffray CompaniesCytokinetics,'s (CYTK) "Overweight" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - November 21 at 3:24 PM
Cytokinetics, Incorporated (CYTK) Price Target Cut to $17.00Cytokinetics, Incorporated (CYTK) Price Target Cut to $17.00
www.americanbankingnews.com - November 21 at 12:00 PM
Cytokinetics, Target of Unusually High Options Trading (CYTK)Cytokinetics, Target of Unusually High Options Trading (CYTK)
www.americanbankingnews.com - November 18 at 2:02 AM
Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock? - Yahoo FinanceIs the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock? - Yahoo Finance
finance.yahoo.com - November 17 at 11:39 PM
Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?
finance.yahoo.com - November 17 at 1:35 PM
Noteworthy Tuesday Option Activity: CYTK, RH, GNENoteworthy Tuesday Option Activity: CYTK, RH, GNE
www.thestreet.com - November 14 at 11:10 PM
Cytokinetics (CYTK) Announces Additional Results From COSMIC ... - StreetInsider.comCytokinetics (CYTK) Announces Additional Results From COSMIC ... - StreetInsider.com
www.streetinsider.com - November 14 at 6:09 PM
Is It Too Late To Buy Cytokinetics Incorporated (CYTK)?Is It Too Late To Buy Cytokinetics Incorporated (CYTK)?
finance.yahoo.com - November 14 at 6:09 PM
Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017
finance.yahoo.com - November 13 at 5:41 PM
Cytokinetics, Incorporated (CYTK) Given Average Rating of "Buy" by BrokeragesCytokinetics, Incorporated (CYTK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 13 at 3:03 PM
ETFs with exposure to Cytokinetics, Inc. : November 8, 2017ETFs with exposure to Cytokinetics, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 12:32 AM
Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 8 at 2:07 AM
Cytokinetics, Incorporated (CYTK) Insider Caryn Gordon Mcdowell Sells 4,260 SharesCytokinetics, Incorporated (CYTK) Insider Caryn Gordon Mcdowell Sells 4,260 Shares
www.americanbankingnews.com - November 6 at 9:22 PM
Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Sessions 2017Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Sessions 2017
finance.yahoo.com - November 6 at 7:03 PM
Stock Traders Purchase High Volume of Put Options on Cytokinetics, (CYTK)Stock Traders Purchase High Volume of Put Options on Cytokinetics, (CYTK)
www.americanbankingnews.com - November 5 at 3:18 AM
Cytokinetics, Incorporated (CYTK) EVP Fady Ibraham Malik Sells 7,321 SharesCytokinetics, Incorporated (CYTK) EVP Fady Ibraham Malik Sells 7,321 Shares
www.americanbankingnews.com - November 3 at 11:29 PM
Robert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (CYTK) StockRobert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (CYTK) Stock
www.americanbankingnews.com - November 3 at 11:28 PM
Noteworthy Wednesday Option Activity: SGEN, CYTK, WRDNoteworthy Wednesday Option Activity: SGEN, CYTK, WRD
www.nasdaq.com - November 1 at 6:44 PM
Cytokinetics, Incorporated to Post FY2017 Earnings of ($2.14) Per Share, Cantor Fitzgerald Forecasts (CYTK)Cytokinetics, Incorporated to Post FY2017 Earnings of ($2.14) Per Share, Cantor Fitzgerald Forecasts (CYTK)
www.americanbankingnews.com - November 1 at 10:00 AM
Cytokinetics, Inc.: Leads amongst peers with strong fundamentalsCytokinetics, Inc.: Leads amongst peers with strong fundamentals
finance.yahoo.com - October 30 at 6:20 PM

SEC Filings

Cytokinetics (NASDAQ:CYTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytokinetics (NASDAQ CYTK) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.